Drug
Ak102
Ak102: highest development phase Phase 3, developed by Akeso. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK102 NCT05260411 | Phase 3 | Hyperlipidemia |
| AK102 NCT04358432 | Phase 2 | Hypercholesterolemia |
| AK102 NCT04173793 | Phase 2 | Heterozygous Familial Hypercholesterolemia |
| AK102 NCT04169386 | Phase 1 | Hypercholesterolaemia |
Latest
No recent events.
Follow Ak102 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.